INSERM U1231, Faculty of Health Sciences, Université de Bourgogne, Dijon, France.
Constitutive Reference Center for Rare Pulmonary Diseases-OrphaLung, University Hospital Dijon-Bourgogne, Dijon, France.
J Clin Invest. 2024 Sep 17;134(18):e183970. doi: 10.1172/JCI183970.
Epigallocatechin gallate (EGCG) is a polyphenol plant metabolite abundant in tea that has demonstrated antifibrotic properties in the lung. In this issue of the JCI, Cohen, Brumwell, and colleagues interrogated the mechanistic action of EGCG by investigating lung biopsies of patients with mild interstitial lung disease (ILD) who had undergone EGCG treatment. EGCG targeted the WNT inhibitor SFRP2, which was enriched in fibrotic fibroblasts and acted as a TGF-β target, with paracrine effects leading to pathologic basal metaplasia of alveolar epithelial type 2 cells. This study emphasizes the epithelial-mesenchymal trophic unit as a central signaling hub in lung fibrosis. Understanding and simultaneous targeting of interlinked signaling pathways, such as TGF-β and WNT, paves the road for future treatment options for pulmonary fibrosis.
没食子酸表没食子儿茶素酯（EGCG）是一种在茶中含量丰富的多酚植物代谢物，已在肺部表现出抗纤维化特性。在本期 JCI 中，Cohen、Brumwell 和同事们通过研究接受 EGCG 治疗的轻度间质性肺病（ILD）患者的肺活检，探究了 EGCG 的作用机制。EGCG 靶向 WNT 抑制剂 SFRP2，后者在纤维化成纤维细胞中富集，并作为 TGF-β 的靶点发挥作用，通过旁分泌作用导致 II 型肺泡上皮细胞的病理性基底化生。这项研究强调了上皮-间充质营养单位作为肺纤维化中中央信号枢纽的作用。理解和同时针对 TGF-β和 WNT 等相互关联的信号通路为肺纤维化的未来治疗选择铺平了道路。
